Trial · NCT04065308
Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma
NCT04065308, Phase 2, Unknown, Seoul National University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma. Trials, record NCT04065308. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04065308
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma
- NCT number
- NCT04065308
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 33 participants, estimated
- Lead sponsor
- Seoul National University Hospital
- Conditions
- Multiple Myeloma in Relapse, Plasmacytoma, Daratumumab
- Interventions
- Drug Combinations
- First posted
- 2019-08-22
- Last updated
- 2019-08-22
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete response rate in terms of plasmacytoma | within 4 weeks after the 3 cycles of combination therapy (daratumumab plus DCEP) | disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow |
| Secondary | Response rate (Complete response + Partial Response) by IMWG criteria | within 4 weeks after the 3 cycles of combination therapy (daratumumab plus DCEP) | Complete response rate in terms of plasmacytoma plus partial response rate by IMWG criteria |
| Secondary | CR rate by IMWG criteria | within 4 weeks after the 3 cycles of combination therapy (daratumumab plus DCEP) | Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow |
| Secondary | Progression free survival | 3,6,12,24 months after the last administration of daratumuamb | from the last administration date of daratumumab to the date of disease progression or date from any cause |
| Secondary | Overall Survival | 3,6,12,24 months after the last administration of daratumuamb | from the last administration date of daratumumab to death from any cause |
| Secondary | Safety and toxicity profile | 3,6,12,24 months the first administration of daratumumab | according to CTCAE version 4.03 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04065308
GET https://conductscience.org/api/trials/v1/NCT04065308/registered